[go: up one dir, main page]

WO2003010308A3 - Control of gene expression - Google Patents

Control of gene expression Download PDF

Info

Publication number
WO2003010308A3
WO2003010308A3 PCT/GB2002/003336 GB0203336W WO03010308A3 WO 2003010308 A3 WO2003010308 A3 WO 2003010308A3 GB 0203336 W GB0203336 W GB 0203336W WO 03010308 A3 WO03010308 A3 WO 03010308A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
polypeptide
binding portion
molecule
control
Prior art date
Application number
PCT/GB2002/003336
Other languages
French (fr)
Other versions
WO2003010308A2 (en
Inventor
Lakjaya Buluwela
David Holmes
Tahereh Kamalati
Jonathan Waxman
Simak Ali
Original Assignee
Gene Expression Technologies L
Lakjaya Buluwela
David Holmes
Tahereh Kamalati
Jonathan Waxman
Simak Ali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Expression Technologies L, Lakjaya Buluwela, David Holmes, Tahereh Kamalati, Jonathan Waxman, Simak Ali filed Critical Gene Expression Technologies L
Priority to AU2002317373A priority Critical patent/AU2002317373A1/en
Publication of WO2003010308A2 publication Critical patent/WO2003010308A2/en
Publication of WO2003010308A3 publication Critical patent/WO2003010308A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of suppressing the expression of a selected endogenous gene in a eukaryotic cell the method comprising introducing into the cell (a) a polypeptide comprising a nucleic acid binding portion which binds to a site at or associated with the selected gene and a modifying portion which comprises a polypeptide or peptidomimetic which is capable of modulating covalent modification of nucleic acid or chromatin, for example a chromatin inactivation portion, or (b) a polynucleotide encoding said polypeptide. The binding of the molecule to nucleic acid may be modulated by a ligand and the molecule may comprise a ligand binding portion. The nucleic acid binding portion may be a nucleic acid binding portion of a nuclear receptor DNA binding protein.
PCT/GB2002/003336 2001-07-24 2002-07-19 Control of gene expression WO2003010308A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002317373A AU2002317373A1 (en) 2001-07-24 2002-07-19 Control of gene expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0117964.7A GB0117964D0 (en) 2001-07-24 2001-07-24 Control of gene expression
GB0117964.7 2001-07-24

Publications (2)

Publication Number Publication Date
WO2003010308A2 WO2003010308A2 (en) 2003-02-06
WO2003010308A3 true WO2003010308A3 (en) 2003-05-08

Family

ID=9919042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/003336 WO2003010308A2 (en) 2001-07-24 2002-07-19 Control of gene expression

Country Status (3)

Country Link
AU (1) AU2002317373A1 (en)
GB (2) GB0117964D0 (en)
WO (1) WO2003010308A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006509010A (en) * 2002-12-05 2006-03-16 インペリアル・カレッジ・イノベイションズ・リミテッド Control of apoptosis
NL1027479C2 (en) * 2004-10-21 2006-05-01 Synvolux Ip B V Protection of biologically active molecules with the help of amphiphiles.
US10351867B2 (en) 2013-03-01 2019-07-16 The Regents Of The University Of California Methods and compositions for targeting RNA polymerases and non-coding RNA biogenesis to specific loci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002019A2 (en) * 1999-06-30 2001-01-11 Imperial College Innovations Limited Control of gene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441483A3 (en) * 1990-01-16 1992-11-19 Baylor College Of Medicine Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors
WO1997011972A1 (en) * 1995-09-28 1997-04-03 The Trustees Of Columbia University In The City Of New York Chimeric dna-binding/dna methyltransferase nucleic acid and polypeptide and uses thereof
CA2316036A1 (en) * 1999-08-27 2001-02-27 Keqiang Wu Repressing gene expression in plants
AU5391401A (en) * 2000-04-28 2001-11-12 Sangamo Biosciences Inc Targeted modification of chromatin structure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002019A2 (en) * 1999-06-30 2001-01-11 Imperial College Innovations Limited Control of gene expression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIEN P-Y ET AL: "A FUSION PROTEIN OF THE ESTROGEN RECEPTOR (ER) AND NUCLEAR RECEPTORCOREPRESSOR (NCOR) STRONGLY INHIBITS ESTROGEN-DEPENDENT RESPONSES IN BREAST CANCER CELLS", MOLECULAR ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 13, no. 12, December 1999 (1999-12-01), pages 2122 - 2136, XP000978743, ISSN: 0888-8809 *
MANTEUFFEL-CYMBOROWSKA MALGORZATA: "Nuclear receptors, their coactivators and modulation of transcription.", ACTA BIOCHIMICA POLONICA, vol. 46, no. 1, 1999, pages 77 - 89, XP009005858, ISSN: 0001-527X *
RAZIN AHARON: "CpG methylation, chromatin structure and gene silencing - a three-way connection.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 17, no. 17, pages 4905 - 4908, XP002233552, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
GB2380195A (en) 2003-04-02
AU2002317373A1 (en) 2003-02-17
WO2003010308A2 (en) 2003-02-06
GB0117964D0 (en) 2001-09-19
GB0216776D0 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
WO2000040615A3 (en) EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
WO2002000692A3 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
PL352332A1 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
NO2007014I2 (en) Anti-VEGF antibody, composition, nucleic acid, vector, host cell, method and drug for medical use
WO2001075087A3 (en) Subtilisin variants
WO2005108615A3 (en) Nucleic-acid programmable protein arrays
WO2005080556A3 (en) Virus purification methods
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
WO2001019981A3 (en) Functional genomics using zinc finger proteins
WO2002006457A3 (en) Novel lipase genes
WO2000053722A3 (en) Delivery of nucleic acids and proteins to cells
WO1998042851A8 (en) Plants with modified growth
WO1998021343A8 (en) Genes encoding telomerase proteins
EE200300100A (en) A polypeptide, a nucleic acid comprising a nucleotide sequence encoding it, a vector and a host cell, a method of making the polypeptide, and a pharmaceutical composition.
DE69808743D1 (en) Netrinrezeptoren
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
WO2004050885A3 (en) Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO2003048308A3 (en) Thermus brockianus nucleic acid polymerases
WO2001036460A3 (en) Methods and means for regulation of gene expression
WO2003010308A3 (en) Control of gene expression
WO1999004266A3 (en) Interactions of atm, atr or dna-pk with p53
WO2000052164A3 (en) Potassium channel molecules and uses therefor
EP0763205A4 (en) Nucleic acid sequences controlling lung cell-specific gene expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PH PL PT RO SD SE SG SI SK SL TJ TM TR TT TZ UG US UZ VN YU ZA

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP